Developer docs
API playgroundTry for free, no card

Search company profiles

国药控股广州有限公司

Full company profile

uuid005bif9

Namestring
国药控股广州有限公司
Legal namestring
国药控股广州有限公司
Company typeenum
Private
Founded yearstring
-
Descriptiontext

国药控股广州有限公司 (Sinopharm Holding Guangzhou Co., Ltd.) is a Guangdong-based subsidiary of Sinopharm Holding Co., Ltd. (listed on Shanghai Stock Exchange 601869 and Hong Kong Stock Exchange 01099), itself controlled by the state-owned Sinopharm Group (国药集团) under SASAC. The company is organized as the group's distribution operations headquarters for South China, headquartered at Liwan District, Guangzhou, and operates under a 'one body, two wings' (一体两翼) strategy combining traditional distribution with retail and innovation businesses.

The company operates six core business lines: (1) traditional pharmaceutical distribution (传统业务) to hospitals, clinics, and pharmacies; (2) medical devices and consumables (器械耗材); (3) retail direct sales (零售直销); (4) retail treatment/clinic services via the SPS+ professional pharmacy chain (零售诊疗); (5) pharmaceutical logistics with cold-chain capability (医药物流); and (6) an innovation business segment covering digital transformation and emerging service models (创新业务). It also operates a proprietary B2B e-commerce platform (511yao.com) for online procurement. Its principal customers are public and non-public hospitals, medical institutions, individual patients through SPS+ pharmacies, and medical device suppliers, with named engagements including Guangzhou Medical University Affiliated Tumor Hospital and BeiGene.

Revenue is generated through transactional fees on pharmaceutical and consumable distribution, plus recurring revenue from professional pharmacy and clinic operations under the SPS+ brand. Go-to-market is sales-led with field sales teams targeting healthcare providers, complemented by tendering participation, industry events, and the e-commerce storefront. The firmographic record lists 88 employees, although the operational scale implied by provincial-wide multi-channel distribution suggests the headcount figure refers to a subset of the workforce. Pricing is not publicly disclosed, consistent with a sector where government centralized procurement and hospital tendering set transaction terms. The company has won the 2023 Zhaopin China Best Employer Award (Guangzhou Best Employer), reflecting investment in employer brand and structured talent development programs (啟航計劃/續航計畫/遠航計畫 for early-career, plus five management-level programs).

Short descriptiontext

Sinopharm Holding Guangzhou Co., Ltd. is a Guangdong Province-based subsidiary of Sinopharm Holding that distributes pharmaceuticals, medical devices, and consumables to hospitals and operates the SPS+ professional pharmacy chain, retail clinics, and the 511yao.com B2B procurement platform across South China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution, medical device supply, pharmaceutical logistics, retail pharmacy services, healthcare procurement
Industry4 codes
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYTLAIAIAA
Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP)
SECONDARYTLALABAF
Pharmaceutical & Life Sciences Cold Chain Storage (2–8°C / CRT)
SECONDARYTLAAAIAB
Pharmaceutical & Biologics Courier (Rx, Specialty Drugs)
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Refrigerated Warehousing and Storage493120
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Pharmaceutical Distribution
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Pharmaceutical Distribution (传统业务)
TypeTransaction Fee
Description

Core pharmaceutical distribution business serving hospitals, clinics, and retail pharmacies across Guangdong Province, covering traditional pharmaceutical products and medical consumables.

sinopharm-gz.com
2Medical Devices and Consumables (器械耗材)
TypeTransaction Fee
Description

Distribution of medical devices and consumables to hospitals and healthcare facilities.

sinopharm-gz.com
3Retail Direct Sales (零售直销)
TypeTransaction Fee
Description

Direct retail sales of pharmaceutical and health products to end consumers.

sinopharm-gz.com
4Retail Treatment/Clinic (零售诊疗)
TypeSubscription Recurring
Description

SPS+ professional pharmacy and retail clinic operations serving individual patients.

sinopharm-gz.com
5Pharmaceutical Logistics (医药物流)
TypeTransaction Fee
Description

Specialized pharmaceutical logistics and cold-chain distribution services.

sinopharm-gz.com
6Innovation Business (创新业务)
TypeTransaction Fee
Description

New and innovative business models including digital transformation initiatives and new pharmaceutical services.

sinopharm-gz.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SPS+国药控股专业药房
Description

Specialized pharmacy brand operated by the company offering pharmaceutical retail and treatment services.

sinopharm-gz.com
Core offering1 text field

Sinopharm Holdings Guangzhou distributes pharmaceuticals, medical devices and consumables to hospitals, clinics and other healthcare institutions across Guangdong Province, while operating the SPS+ Professional Pharmacy retail chain and providing temperature-controlled pharmaceutical logistics with cold chain capabilities. The company serves as the regional distribution arm of Sinopharm Holding (Shanghai: 601869, HK: 01099), supporting both institutional buyers and retail consumers through multiple integrated channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • AI talent training program launched covering management vision enhancement, practical tool application, and technology frontier analysis for employees at all levels.
+1 more record
Product overview1 text field

国药控股广州有限公司 (Sinopharm Guanzhou Co., Ltd.) operates as a comprehensive pharmaceutical distribution and healthcare services provider within the Sinopharm Group. The company's product portfolio centers on pharmaceutical wholesale distribution, medical devices and consumables, and retail pharmacy operations through its SPS+ professional pharmacy chain. Additional offerings include pharmaceutical logistics with cold chain capabilities, direct retail sales, retail medical consultation services, innovative healthcare business models, and a B2B e-commerce platform (511yao.com). The business operates under an integrated 'one body with two wings' strategy, combining traditional pharmaceutical distribution with innovation-driven healthcare services.

Product and service1 record
1Traditional Pharmaceutical Distribution
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1百度飞桨(广州)人工智能产业赋能中心 (Baidu PaddlePaddle Guangzhou AI Industry Empowerment Center)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

国控广州 organized field visits to Baidu PaddlePaddle (Guangzhou) AI Industry Empowerment Center as part of its AI talent development program, enabling employees to experience AI technology applications in industrial scenarios and accumulate practical knowledge for technology-business integration.

sinopharm-gz.com
2百济神州 (BeiGene)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Jointly organized '协同—颠覆性价值创造' (Collaboration - Disruptive Value Creation) training on May 27, 2025, with approximately 40 core procurement and sales staff participating. BeiGene provided a specialized instructor to deliver training on collaborative thinking, tools, and methodology application, aiming to optimize purchase-sales coordination and strategic cooperation between the two companies.

sinopharm-gz.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

University-enterprise cooperation for talent cultivation and recruitment, part of 国控广州's school-enterprise cooperation initiative.

4广州中医药大学 (Guangzhou University of Chinese Medicine)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

University-enterprise cooperation for talent cultivation and recruitment.

sinopharm-gz.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

University-enterprise cooperation for talent cultivation and recruitment.

6南方医科大学 (Southern Medical University)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

University-enterprise cooperation for talent cultivation and recruitment.

sinopharm-gz.com
7广州医科大学 (Guangzhou Medical University)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

University-enterprise cooperation for talent cultivation and recruitment.

sinopharm-gz.com
8广东食品药品职业学院 (Guangdong Food and Drug Vocational College)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

On April 26, 2024, signed a school-enterprise cooperation agreement and held a产学研基地 (industry-academia-research base) unveiling ceremony. The partnership aims to cultivate applied and compound talents through co-development of talent chain, innovation chain, and industry chain.

sinopharm-gz.com
9南昌大学软件学院 (Nanchang University Software College)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

On December 23, 2024, signed a graduate employment base cooperation agreement. The partnership focuses on software engineering talent cultivation, IT talent recruitment, and industry-academia-research cooperation, with university representatives visiting SPS+ professional pharmacies.

sinopharm-gz.com
10北京理工大学化学与化工学院 (Beijing Institute of Technology School of Chemistry and Chemical Engineering)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

On February 19, 国控广州 and Beijing Institute of Technology School of Chemistry and Chemical Engineering held a university-enterprise cooperation exchange seminar to explore talent cultivation models and build closer cooperation relationships.

sinopharm-gz.com
11广州医科大学附属肿瘤医院 (Guangzhou Medical University Affiliated Tumor Hospital)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

On November 25, 2025, launched the Day Infusion Center project (日间输注中心项目) jointly, aiming to create a new model of safe, efficient, and humanized infusion services for cancer patients.

sinopharm-gz.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1柳州医药股份有限公司 (Liuzhou Pharmaceutical)
TypeRegional player
Description

Regional pharmaceutical distributor (SSE:603368) headquartered in Guangxi. Adjacent geography to Guangdong and overlapping distribution model serving hospitals and retail pharmacies in southern China.

2重药控股股份有限公司 (Sinopharm Chongqing Pharmaceutical / 重药控股)
TypeDirect peer
Description

Another regional pharmaceutical distribution subsidiary under the Sinopharm Group (SSE:000950), operating across Southwest China. Directly comparable as a peer regional platform within the same parent group with similar hospital distribution, retail pharmacy, and logistics model.

3国药控股股份有限公司 (Sinopharm Holding Co., Ltd.)
TypeBroad incumbent
Description

Direct parent (SSE:601869, HKEX:01099) and China's largest pharmaceutical distributor; same core business of hospital distribution, retail pharmacy, and logistics across the country. Most directly comparable peer because the subject operates as a wholly-owned regional platform under this group.

4九州通医药集团股份有限公司 (Jointown Pharmaceutical Group)
TypeDirect peer
Description

Privately-controlled top-3 pharmaceutical distributor (SSE:600998) with strong presence among private hospitals, retail chains, and small clinics in southern China. Competes aggressively on price and customer service, particularly for non-public medical institutions.

TypeDirect peer
Description

One of China's 'Big 3' pharmaceutical distributors (SSE:601607, HKEX:02607). Competes with Sinopharm Holding's regional subsidiaries for hospital tenders, distribution contracts, and retail pharmacy acquisitions across southern China. Operates an integrated distribution + manufacturing + retail model.

6华润医药集团有限公司 (China Resources Pharmaceutical Group)
TypeDirect peer
Description

Major state-affiliated pharmaceutical distribution and manufacturing group listed in Hong Kong (HKEX:03320). Head-to-head competitor with Sinopharm in hospital drug distribution and operates its own retail pharmacy chain across China.

7嘉事堂药业股份有限公司 (Cachet Pharmaceutical)
TypeEmerging player
Description

Beijing-based pharmaceutical distributor with growing medical device distribution business (SZSE:002462). Compares on the medical device and consumable distribution segment (器械耗材), where Sinopharm Guangzhou is also building share.

TypeDirect peer
Description

State-owned pharmaceutical distribution and international trading group under Sinopharm Group (SSE:600056). Engaged in pharmaceutical distribution, manufacturing, and international trade; competes for institutional and hospital tenders in multiple regions.

9鹭燕医药股份有限公司 (Luyan Pharmaceutical)
TypeRegional player
Description

Regional pharmaceutical distributor (SZSE:002788) headquartered in Fujian with distribution across southern and eastern China. Comparable as a regional wholesaler/retailer focused on hospital channel.

10英特集团 (Int'l Drug Group / 浙江省英特集团)
TypeRegional player
Description

Regional pharmaceutical distributor (SZSE:000411) primarily serving Zhejiang and eastern China. Comparable as a regional wholesaler with retail pharmacy operations, providing a peer benchmark for regional platform economics outside of Guangdong.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

国药控股广州有限公司

Pharmaceutical Distributionsinopharm-gz.com

Sinopharm Holding Guangzhou Co., Ltd. is a Guangdong Province-based subsidiary of Sinopharm Holding that distributes pharmaceuticals, medical devices, and consumables to hospitals and operates the SPS+ professional pharmacy chain, retail clinics, and the 511yao.com B2B procurement platform across South China.

What 国药控股广州有限公司 does

国药控股广州有限公司 (Sinopharm Holding Guangzhou Co., Ltd.) is a Guangdong-based subsidiary of Sinopharm Holding Co., Ltd. (listed on Shanghai Stock Exchange 601869 and Hong Kong Stock Exchange 01099), itself controlled by the state-owned Sinopharm Group (国药集团) under SASAC. The company is organized as the group's distribution operations headquarters for South China, headquartered at Liwan District, Guangzhou, and operates under a 'one body, two wings' (一体两翼) strategy combining traditional distribution with retail and innovation businesses.

The company operates six core business lines: (1) traditional pharmaceutical distribution (传统业务) to hospitals, clinics, and pharmacies; (2) medical devices and consumables (器械耗材); (3) retail direct sales (零售直销); (4) retail treatment/clinic services via the SPS+ professional pharmacy chain (零售诊疗); (5) pharmaceutical logistics with cold-chain capability (医药物流); and (6) an innovation business segment covering digital transformation and emerging service models (创新业务). It also operates a proprietary B2B e-commerce platform (511yao.com) for online procurement. Its principal customers are public and non-public hospitals, medical institutions, individual patients through SPS+ pharmacies, and medical device suppliers, with named engagements including Guangzhou Medical University Affiliated Tumor Hospital and BeiGene.

Revenue is generated through transactional fees on pharmaceutical and consumable distribution, plus recurring revenue from professional pharmacy and clinic operations under the SPS+ brand. Go-to-market is sales-led with field sales teams targeting healthcare providers, complemented by tendering participation, industry events, and the e-commerce storefront. The firmographic record lists 88 employees, although the operational scale implied by provincial-wide multi-channel distribution suggests the headcount figure refers to a subset of the workforce. Pricing is not publicly disclosed, consistent with a sector where government centralized procurement and hospital tendering set transaction terms. The company has won the 2023 Zhaopin China Best Employer Award (Guangzhou Best Employer), reflecting investment in employer brand and structured talent development programs (啟航計劃/續航計畫/遠航計畫 for early-career, plus five management-level programs).

国药控股广州有限公司 firmographics

Firmographics
Name
国药控股广州有限公司
Legal name
国药控股广州有限公司
Website
https://sinopharm-gz.com
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Short description
Sinopharm Holding Guangzhou Co., Ltd. is a Guangdong Province-based subsidiary of Sinopharm Holding that distributes pharmaceuticals, medical devices, and consumables to hospitals and operates the SPS+ professional pharmacy chain, retail clinics, and the 511yao.com B2B procurement platform across South China.
Ownership category
akta.pro rank

国药控股广州有限公司 industry classification

Industry
Product category
Pharmaceutical Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Refrigerated Warehousing and Storage (493120)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYTLAIAIAA
Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP)
SECONDARYTLALABAF
Pharmaceutical & Life Sciences Cold Chain Storage (2–8°C / CRT)
SECONDARYTLAAAIAB
Pharmaceutical & Biologics Courier (Rx, Specialty Drugs)

Keywords

  • Pharmaceutical distribution
  • Medical device supply
  • Pharmaceutical logistics
  • Retail pharmacy services
  • Healthcare procurement

Where 国药控股广州有限公司 is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices1 record

Markets served

国药控股广州有限公司 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Distribution (传统业务): Core pharmaceutical distribution business serving hospitals, clinics, and retail pharmacies across Guangdong Province, covering traditional pharmaceutical products and medical consumables.
  2. Medical Devices and Consumables (器械耗材): Distribution of medical devices and consumables to hospitals and healthcare facilities.
  3. Retail Direct Sales (零售直销): Direct retail sales of pharmaceutical and health products to end consumers.
  4. Retail Treatment/Clinic (零售诊疗): SPS+ professional pharmacy and retail clinic operations serving individual patients.
  5. Pharmaceutical Logistics (医药物流): Specialized pharmaceutical logistics and cold-chain distribution services.
  6. Innovation Business (创新业务): New and innovative business models including digital transformation initiatives and new pharmaceutical services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

国药控股广州有限公司 product offering

Product offering

Core offering

Sinopharm Holdings Guangzhou distributes pharmaceuticals, medical devices and consumables to hospitals, clinics and other healthcare institutions across Guangdong Province, while operating the SPS+ Professional Pharmacy retail chain and providing temperature-controlled pharmaceutical logistics with cold chain capabilities. The company serves as the regional distribution arm of Sinopharm Holding (Shanghai: 601869, HK: 01099), supporting both institutional buyers and retail consumers through multiple integrated channels.

Product overview

国药控股广州有限公司 (Sinopharm Guanzhou Co., Ltd.) operates as a comprehensive pharmaceutical distribution and healthcare services provider within the Sinopharm Group. The company's product portfolio centers on pharmaceutical wholesale distribution, medical devices and consumables, and retail pharmacy operations through its SPS+ professional pharmacy chain. Additional offerings include pharmaceutical logistics with cold chain capabilities, direct retail sales, retail medical consultation services, innovative healthcare business models, and a B2B e-commerce platform (511yao.com). The business operates under an integrated 'one body with two wings' strategy, combining traditional pharmaceutical distribution with innovation-driven healthcare services.

Differentiator

Problem solved

Functional benefit

Brands

  • SPS+国药控股专业药房: Specialized pharmacy brand operated by the company offering pharmaceutical retail and treatment services.

Products and services

  • Traditional Pharmaceutical Distribution

Quantifiable outcome

  • AI talent training program launched covering management vision enhancement, practical tool application, and technology frontier analysis for employees at all levels.
  • +1 more outcomes

Companies that use 国药控股广州有限公司

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

国药控股广州有限公司 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

国药控股广州有限公司 partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • 百度飞桨(广州)人工智能产业赋能中心 (Baidu PaddlePaddle Guangzhou AI Industry Empowerment Center)minorStrategic or Co-development Partner · 1 January 2025国控广州 organized field visits to Baidu PaddlePaddle (Guangzhou) AI Industry Empowerment Center as part of its AI talent development program, enabling employees to experience AI technology applications in industrial scenarios and accumulate practical knowledge for technology-business integration.
  • 百济神州 (BeiGene)coreStrategic or Co-development Partner · 1 January 2025Jointly organized '协同—颠覆性价值创造' (Collaboration - Disruptive Value Creation) training on May 27, 2025, with approximately 40 core procurement and sales staff participating. BeiGene provided a specialized instructor to deliver training on collaborative thinking, tools, and methodology application, aiming to optimize purchase-sales coordination and strategic cooperation between the two companies.
  • 暨南大学 (Jinan University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment, part of 国控广州's school-enterprise cooperation initiative.
  • 广州中医药大学 (Guangzhou University of Chinese Medicine)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
  • 广东药科大学 (Guangdong Pharmaceutical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
  • 南方医科大学 (Southern Medical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
  • 广州医科大学 (Guangzhou Medical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
  • 广东食品药品职业学院 (Guangdong Food and Drug Vocational College)minorStrategic or Co-development Partner · 1 January 2025On April 26, 2024, signed a school-enterprise cooperation agreement and held a产学研基地 (industry-academia-research base) unveiling ceremony. The partnership aims to cultivate applied and compound talents through co-development of talent chain, innovation chain, and industry chain.
  • 南昌大学软件学院 (Nanchang University Software College)minorStrategic or Co-development Partner · 1 January 2025On December 23, 2024, signed a graduate employment base cooperation agreement. The partnership focuses on software engineering talent cultivation, IT talent recruitment, and industry-academia-research cooperation, with university representatives visiting SPS+ professional pharmacies.
  • 北京理工大学化学与化工学院 (Beijing Institute of Technology School of Chemistry and Chemical Engineering)minorStrategic or Co-development Partner · 1 January 2025On February 19, 国控广州 and Beijing Institute of Technology School of Chemistry and Chemical Engineering held a university-enterprise cooperation exchange seminar to explore talent cultivation models and build closer cooperation relationships.
  • 广州医科大学附属肿瘤医院 (Guangzhou Medical University Affiliated Tumor Hospital)coreStrategic or Co-development Partner · 1 January 2025On November 25, 2025, launched the Day Infusion Center project (日间输注中心项目) jointly, aiming to create a new model of safe, efficient, and humanized infusion services for cancer patients.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

国药控股广州有限公司 competitors and assessment

Company assessment

Regional players

  • 柳州医药股份有限公司 (Liuzhou Pharmaceutical): Regional pharmaceutical distributor (SSE:603368) headquartered in Guangxi. Adjacent geography to Guangdong and overlapping distribution model serving hospitals and retail pharmacies in southern China.
  • 鹭燕医药股份有限公司 (Luyan Pharmaceutical): Regional pharmaceutical distributor (SZSE:002788) headquartered in Fujian with distribution across southern and eastern China. Comparable as a regional wholesaler/retailer focused on hospital channel.
  • 英特集团 (Int'l Drug Group / 浙江省英特集团): Regional pharmaceutical distributor (SZSE:000411) primarily serving Zhejiang and eastern China. Comparable as a regional wholesaler with retail pharmacy operations, providing a peer benchmark for regional platform economics outside of Guangdong.

Direct peers

  • 重药控股股份有限公司 (Sinopharm Chongqing Pharmaceutical / 重药控股): Another regional pharmaceutical distribution subsidiary under the Sinopharm Group (SSE:000950), operating across Southwest China. Directly comparable as a peer regional platform within the same parent group with similar hospital distribution, retail pharmacy, and logistics model.
  • 九州通医药集团股份有限公司 (Jointown Pharmaceutical Group): Privately-controlled top-3 pharmaceutical distributor (SSE:600998) with strong presence among private hospitals, retail chains, and small clinics in southern China. Competes aggressively on price and customer service, particularly for non-public medical institutions.
  • 上海医药集团股份有限公司 (Shanghai Pharmaceuticals Holding): One of China's 'Big 3' pharmaceutical distributors (SSE:601607, HKEX:02607). Competes with Sinopharm Holding's regional subsidiaries for hospital tenders, distribution contracts, and retail pharmacy acquisitions across southern China. Operates an integrated distribution + manufacturing + retail model.
  • 华润医药集团有限公司 (China Resources Pharmaceutical Group): Major state-affiliated pharmaceutical distribution and manufacturing group listed in Hong Kong (HKEX:03320). Head-to-head competitor with Sinopharm in hospital drug distribution and operates its own retail pharmacy chain across China.
  • 中国医药健康产业股份有限公司 (China National Pharmaceutical Health Industry / China Meheco): State-owned pharmaceutical distribution and international trading group under Sinopharm Group (SSE:600056). Engaged in pharmaceutical distribution, manufacturing, and international trade; competes for institutional and hospital tenders in multiple regions.

Broad incumbents

  • 国药控股股份有限公司 (Sinopharm Holding Co., Ltd.): Direct parent (SSE:601869, HKEX:01099) and China's largest pharmaceutical distributor; same core business of hospital distribution, retail pharmacy, and logistics across the country. Most directly comparable peer because the subject operates as a wholly-owned regional platform under this group.

Emerging players

  • 嘉事堂药业股份有限公司 (Cachet Pharmaceutical): Beijing-based pharmaceutical distributor with growing medical device distribution business (SZSE:002462). Compares on the medical device and consumable distribution segment (器械耗材), where Sinopharm Guangzhou is also building share.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

国药控股广州有限公司 social profiles

Digital presence

国药控股广州有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

国药控股广州有限公司 leadership team

Management profile

Number of profiles

Profiles4 records

国药控股广州有限公司 subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

国药控股广州有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

国药控股广州有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 国药控股广州有限公司

What does 国药控股广州有限公司 do?

Sinopharm Holdings Guangzhou distributes pharmaceuticals, medical devices and consumables to hospitals, clinics and other healthcare institutions across Guangdong Province, while operating the SPS+ Professional Pharmacy retail chain and providing temperature-controlled pharmaceutical logistics with cold chain capabilities. The company serves as the regional distribution arm of Sinopharm Holding (Shanghai: 601869, HK: 01099), supporting both institutional buyers and retail consumers through multiple integrated channels.

Is 国药控股广州有限公司 a public or private company?

国药控股广州有限公司 is a private company. It is classified as corporate owned and is currently operating.

When was 国药控股广州有限公司 founded?

国药控股广州有限公司 was founded in -1. It employs 51 to 100 people.

Where is 国药控股广州有限公司 based?

国药控股广州有限公司 is headquartered in Guangzhou, China, in the Asia region.

How does 国药控股广州有限公司 make money?

Six revenue lines are on record. Pharmaceutical Distribution (传统业务) is the primary driver. The others are medical Devices and Consumables (器械耗材), retail Direct Sales (零售直销), retail Treatment/Clinic (零售诊疗), pharmaceutical Logistics (医药物流) and innovation Business (创新业务).

Who are 国药控股广州有限公司's main competitors?

Regional players on record are 柳州医药股份有限公司 (Liuzhou Pharmaceutical), 鹭燕医药股份有限公司 (Luyan Pharmaceutical) and 英特集团 (Int'l Drug Group / 浙江省英特集团). Direct peers are 重药控股股份有限公司 (Sinopharm Chongqing Pharmaceutical / 重药控股), 九州通医药集团股份有限公司 (Jointown Pharmaceutical Group), 上海医药集团股份有限公司 (Shanghai Pharmaceuticals Holding), 华润医药集团有限公司 (China Resources Pharmaceutical Group) and 中国医药健康产业股份有限公司 (China National Pharmaceutical Health Industry / China Meheco). 国药控股股份有限公司 (Sinopharm Holding Co., Ltd.) is listed as a broad incumbent. 嘉事堂药业股份有限公司 (Cachet Pharmaceutical) is listed as an emerging player.

Does 国药控股广州有限公司 have an API?

No public API is recorded for 国药控股广州有限公司.

What industry is 国药控股广州有限公司 in?

国药控股广州有限公司's product category is Pharmaceutical Distribution. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant), with a secondary code of TLAIAIAA, Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP). Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales